Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Na Wang, Tao Yang, Jie Li & Xianfeng Zhang. (2019) Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Diabetes, Metabolic Syndrome and Obesity 12, pages 1513-1526.
Read now
Read now
Takashi Kadowaki, Satsuki Muto, Yoshiumi Ouchi, Ryutaro Shimazaki & Yutaka Seino. (2017) Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension. Expert Opinion on Pharmacotherapy 18:18, pages 1903-1919.
Read now
Read now
Dieter Ayers, Steve Kanters, Rachel Goldgrub, Monica Hughes, Ryo Kato & Nana Kragh. (2017) Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients. Current Medical Research and Opinion 33:9, pages 1653-1661.
Read now
Read now
Awadhesh Kumar Singh & Ritu Singh. (2016) Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: rationale and evidences. Expert Review of Clinical Pharmacology 9:4, pages 605-616.
Read now
Read now
Daisuke Yabe & Yutaka Seino. (2016) Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 15:2, pages 249-264.
Read now
Read now
Yoshifumi Saisho. (2015) Alogliptin benzoate for management of type 2 diabetes. Vascular Health and Risk Management 11, pages 229-243.
Read now
Read now
André J Scheen. (2015) A review of gliptins for 2014. Expert Opinion on Pharmacotherapy 16:1, pages 43-62.
Read now
Read now
Yutaka Seino & Daisuke Yabe. (2014) Alogliptin for the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 9:6, pages 547-559.
Read now
Read now
Articles from other publishers (19)
Zhenhong Pan, Yan Yang & Jingjing Zhang. (2020) Efficacy and safety of DPP‐IV inhibitors combined with basal insulin in the treatment of type 2 diabetes. Journal of Diabetes 13:5, pages 375-389.
Crossref
Crossref
Katsuya Shibuki, Shuji Shimada & Takao Aoyama. (2020) Meta-Analysis of 11 Heterogeneous Studies regarding Dipeptidyl Peptidase 4 Inhibitor Add-On Therapy for Type 2 Diabetes Mellitus Patients Treated with Insulin. Journal of Diabetes Research 2020, pages 1-12.
Crossref
Crossref
Jin Yang, Qing Tian, Yuexin Tang, Arvind K. Shah, Ruya Zhang, Guojuan Chen, Ye Zhang, Swapnil Rajpathak & Tianpei Hong. (2020) Effect of Dipeptidyl Peptidase 4 Inhibitors Used in Combination with Insulin Treatment in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis. Diabetes Therapy 11:10, pages 2371-2382.
Crossref
Crossref
Kohei Kaku, Koichi Kisanuki, Mari Shibata & Takashi Oohira. (2019) Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus. Drug Safety 42:11, pages 1311-1327.
Crossref
Crossref
Fernando Gomez-Peralta, Cristina Abreu, Sara Gomez-Rodriguez, Rafael J. Barranco & Guillermo E. Umpierrez. (2018) Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios. Diabetes Therapy 9:5, pages 1775-1789.
Crossref
Crossref
Wenjia Yang, Xiaoling Cai, Xueying Gao, Yifei Chen, Ling Chen & Linong Ji. (2018) Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis. Journal of Diabetes Investigation 9:4, pages 813-821.
Crossref
Crossref
Jeong-Hwa Yoon, Se Hee Min, Chang Ho Ahn, Young Min Cho & Seokyung Hahn. (2018) Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis. Scientific Reports 8:1.
Crossref
Crossref
Carolyn F. Deacon. (2018) A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials. Diabetes, Obesity and Metabolism 20, pages 34-46.
Crossref
Crossref
Yuli Cai, Tianshu Zeng, Zhongyuan Wen & Lulu Chen. (2017) Ethnic Differences in Efficacy and Safety of Alogliptin: A Systematic Review and Meta-Analysis. Diabetes Therapy 9:1, pages 177-191.
Crossref
Crossref
Se Hee Min, Jeong-Hwa Yoon, Seokyung Hahn & Young Min Cho. (2017) Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes/Metabolism Research and Reviews 33:1, pages e2818.
Crossref
Crossref
Lingyu He, Shu Liu, Chun Shan, Yingmei Tu, Zhengqing Li & Xiaohua Douglas Zhang. (2016) Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis. BMC Pharmacology and Toxicology 17:1.
Crossref
Crossref
Rimke C Vos, Mariëlle JP van Avendonk, Hanneke Jansen, Alexander Nicolaas N Goudswaard, Maureen van den Donk, Kees Gorter, Anneloes Kerssen & Guy EHM Rutten. (2016) Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Zhuo Li, Haiyan Li, Caifen Wang, Jianghui Xu, Vikramjeet Singh, Dawei Chen & Jiwen Zhang. (2016) Sodium dodecyl sulfate/ β -cyclodextrin vesicles embedded in chitosan gel for insulin delivery with pH-selective release. Acta Pharmaceutica Sinica B 6:4, pages 344-351.
Crossref
Crossref
Yeong Gi Kim, Se Hee Min, Seokyung Hahn, Tae Jung Oh, Kyong Soo Park & Young Min Cho. (2016) Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 116, pages 86-95.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:12, pages 1225-1238.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:10, pages 999-1024.
Crossref
Crossref
Gillian M. Keating. (2015) Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 75:7, pages 777-796.
Crossref
Crossref
Hiromi HamamotoKoji NakanishiMitsuhiko Noda. (2015) Analyzing the Factors Contributing to Withdrawal from Insulin Therapy following Additional Administration of Alogliptin: Retrospective Study after Removing Glucotoxicity with Insulin. Japanese Clinical Medicine 6, pages JCM.S27202.
Crossref
Crossref
Alisa K. Escaño. 2015. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
521
537
.